Training Through Perimenopause: The Complete Guide
What the evidence actually says — about hormones, aerobic training, bone density, nutrition, and where to start.
Perimenopausal women are one of the most aggressively marketed-to demographics in the wellness space right now. Cortisol fear. Zone 2 panic. “Cardio kills your hormones.” Fasting windows calibrated to your cycle. Supplement stacks promising to restore what menopause is taking. All the while, these women are actually trying to navigate a genuinely challenging biological transition.
.
Much of what is said in various social spheres is either wrong, wildly overstated, or designed to monetize your uncertainty.
Yes, I’m a man… but I’ve been an Orthopedic Surgeon for nearly 3 decades. I’ve helped hundreds of women with many orthopedic manifestations of this transition, and our patients have worked with a menopause expert in my office when her expertise is needed. We’ve been quite the team for a while.
I’ve written extensively about this — the orthopedic manifestations, tendon and joint pain, the misinformation problem, and the broader case for why women remain highly capable of building strength and improving fitness through and beyond menopause.
This article goes further. It covers the hormone therapy evidence in the detail it deserves, breaks down what the research actually says about aerobic training and the cortisol myth, explains the Liftmor protocol and why it matters for bone density, addresses nutrition and protein, and gives you a concrete framework for where to start — wherever you are right now. Furthermore, a downloadable guide is available at the end.
The biology of adaptation does not abandon you at perimenopause. But you do need the right information to work with it.
What Actually Changes — and What Doesn’t
Perimenopause typically begins in the mid-to-late 40s, though it can start earlier. It is defined by fluctuating and eventually declining estrogen and progesterone, irregular menstrual cycles, and a range of symptoms that vary enormously between women — hot flashes, sleep disruption, mood changes, changes in body composition, joint sensitivity, and altered recovery from exercise.
What changes in terms of training physiology? Tendons become more sensitive to strain and injury. Recovery tends to take longer, while muscle protein synthesis becomes slightly less efficient, meaning the anabolic signal from training requires a more deliberate nutritional response. Body fat distribution shifts, with more accumulation centrally. Bone density begins to decline more rapidly in the years immediately following menopause, particularly at the spine and hip. Cardiovascular risk profile worsens — women catch up to men remarkably quickly once estrogen declines.
What does not change: the fundamental mechanisms of adaptation. Muscle still responds to progressive overload. Tendons still remodel in response to load. Cardiovascular fitness continues to improve with appropriate training. Bone still responds to mechanical stress. The ceiling may shift, and the timeline for recovery may extend, but the biology of getting stronger and fitter remains intact. This is one of the most consistent findings in the exercise science literature for this population, and it is worth holding onto when the noise online makes it sound like your body has become something entirely different.
Hormone Therapy: The Evidence, the Timing, and the Conversation to Have
The hormone therapy story is more complicated than either side of the online debate typically acknowledges — and getting it right matters, because the overcorrection from the Women’s Health Initiative (WHI) study left a generation of women and physicians unnecessarily frightened of a therapy that, for the right candidate at the right time, carries a reasonable evidence base.
What the WHI actually showed — and what it didn’t
The WHI, published in JAMA in 2002, found increased risks of breast cancer, cardiovascular events, and stroke with combined estrogen-progestin therapy. The study was large, randomized, and influential — and it produced a dramatic decline in HRT prescribing that persisted for over a decade. What received less attention was that the average age of participants at enrollment was 63 (this matters), and many were more than 10 years past menopause. The WHI was not a study of perimenopause or early menopause. It was a study of older postmenopausal women — a meaningfully different population with meaningfully different baseline cardiovascular risk.
The timing hypothesis
Reanalysis of WHI data, along with the KEEPS trial and — most importantly — the ELITE trial, established what is now called the “timing hypothesis”: the cardiovascular effects of HRT differ substantially depending on when therapy is initiated relative to menopause onset.
The ELITE trial (Hodis et al., NEJM 2016) was a randomized, placebo-controlled trial that enrolled women within 6 years of menopause (“early”) and more than 10 years past menopause (“late”). Early initiators showed significantly slower progression of subclinical atherosclerosis — measured by carotid intima-media thickness — compared to placebo. Late initiators showed no benefit and a trend toward harm. This RCT data supports the conclusion that initiating HRT within ten years of menopause onset, or before age 60, carries a cardiovascular profile that looks substantially different from what the WHI found.
What about cognition?
The cognitive picture is more uncertain, and I want to be direct about that. The WHI Memory Study (WHIMS) — the cognitive substudy of WHI — actually found increased risk of dementia in women over 65 initiating HRT. Again, this was an older, late-initiation population. Observational studies and smaller trials suggest a window during which estrogen may support cognitive health and potentially reduce dementia risk, but there is no large RCT showing definitively that HRT initiated at perimenopause prevents cognitive decline. The COGNATE trial and others are ongoing. The honest statement, supported by the current evidence, is that early initiation may support cognitive health — but this cannot be claimed as an established RCT fact, and you should not hear it framed that way by anyone.
The conversation to have
For women without contraindications — no personal history of breast cancer, no unexplained vaginal bleeding, no active cardiovascular disease or clotting disorders — initiated within ten years of menopause onset or before age 60, the evidence is reasonable and, for many women, meaningful. This is a nuanced conversation that belongs with your GYN or GP, who knows your history. What I’d encourage is going into that conversation informed rather than frightened by a 2002 headline. If your physician dismisses HRT categorically without discussing the timing hypothesis, it is worth gently pushing back.
No matter how the conversation goes about hormone therapy, one thing remains especially important— exercise. Hormone therapy, for women who pursue it, is not a substitute for training. Women build strength, improve aerobic fitness, and protect bone density with or without HRT. The exercise prescription does not change based on your hormone therapy status. Both matter, and neither replaces the other.
Members: What follows is for paid subscribers — the aerobic training evidence, the cortisol myth sourced and taken apart, the Liftmor protocol and why walking isn't enough for bone density, a detailed look at protein and nutrition for this population, and a concrete Enough / Better / Optimal exercise framework for where to start. Paid subscribers also receive the downloadable Perimenopausal Training Guide at the end.
